- Category
- Small (2024-25)
- Udyam number
- UDYAM-MH-33-0313779

About Eiko Lifesciences Limited
Data last updated:
Eiko Lifesciences Limited is a public limited company based in Thane, Maharashtra, India. It operates in the specialty chemicals segment of the chemicals and materials sector. It was incorporated on 07 January 1977 and has been in existence for over 49 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L65993MH1977PLC258134. Its GSTIN is 27AAACN0917C1ZZ (Maharashtra). It is a listed company as per MCA records. Its shares are listed on BSE: 540204.
The company has an authorised share capital of ₹20 Cr and a paid-up capital of ₹14.65 Cr. It was formerly known as Ornate Ventures Limited and Narendra Investments (Delhi) Limited. It is led by directors including Umesh Ravindranath More (Whole-Time Director) and Sumukh Prabhakar Vartak (Whole-Time Director).
Its last annual general meeting (AGM) was held on 05 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 604 Centrum Opp. Tmc Office Near Satkar Grande Hotel Wagle Estate, Thane, Maharashtra, India – 400604.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹52.57 Cr, a growth of 39.6% compared to the previous year. For the same year it recorded a net profit of ₹5.31 Cr (net margin 10.1%) and EBITDA of ₹7.32 Cr (EBITDA margin 13.9%). The net worth stands at ₹68.79 Cr (up 21.1% YoY). Total assets are valued at ₹74.56 Cr (up 24.7% YoY).
The company is associated with 2 brands: Eiko LifeSciences Limited and Narendra Investments. As per MCA filings, the company has open charges of ₹10 Cr and satisfied charges of ₹8 Cr on record. The company has 48 deals on record (47 market trades, 1 funding round), with disclosed funding of ₹24.95 Cr; the latest was in June 2025. Its 7 peer companies in the Chemicals industry (API Manufacturers, Lifesciences, Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 4 smaller; the largest is Allegro Speciality Chemicals Private Limited with revenue of ₹38.95 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2021, listing 6 overdue payments to 2 micro and small suppliers.
Eiko Lifesciences Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-33-0313779). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website eikolifesciences.com.
Company details
Name history
Eiko Lifesciences has undergone 4 name changes throughout its history. The current legal name is Eiko Lifesciences Limited.
| Company Name | Status |
|---|---|
| Eiko Lifesciences Limited | Current |
| Ornate Ventures Limited | Previous |
| Narendra Investments (Delhi) Limited | Previous |
| Odin Ventures Limited | Previous |
CIN history
Eiko Lifesciences has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L65993MH1977PLC258134, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L65993MH1977PLC258134 | Current |
| L65993DL1977PLC008460 | Previous |
| U65993DL1977PLC008460 | Previous |
Recognitions & Rankings of Eiko Lifesciences
Contact details
Eiko Lifesciences Limited's registered office is in Thane, Maharashtra. Its website is eikolifesciences.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address604 Centrum Opp. Tmc Office Near Satkar Grande Hotel Wagle Estate, Thane, Maharashtra, India – 400604
- IndustryChemicals and Materials, Specialty Chemicals
To see the full contact details of Eiko Lifesciences Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Eiko Lifesciences operates two associated brands: Eiko LifeSciences Limited and Narendra Investments. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Functions as an investment management firm handling diversified funds and portfolios. | narendrainvestment.com | |
| Manufacturing and exporting of speciality chemicals and pharma intermediates in India. | eikolifesciences.com |
Business activity
The main business activity of Eiko Lifesciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Eiko Lifesciences Limited, buy the company report.
Financials of Eiko Lifesciences Limited
FY 2025-26 filings availableEiko Lifesciences Limited reported revenue of ₹52.57 Cr (up 39.6% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 52.57 | 37.66 | 10.40 | 4.27 | 2.36 |
| Revenue growth | +39.6% | - | +143.6% | +80.9% | - |
| EBITDA | 7.32 | 2.76 | (4.50) | (0.68) | 0.37 |
| EBITDA margin | +13.9% | +7.3% | -43.3% | -15.9% | +15.7% |
| Profit before tax | 7.10 | 3.05 | (4.92) | (1.00) | 0.24 |
| Net profit | 5.31 | 1.86 | (1.89) | (0.45) | 0.19 |
| Net profit margin | +10.1% | +4.9% | -18.2% | -10.5% | +8.1% |
| EPS (₹) | 3.71 | 1.68 | (4.99) | 0.00 | 0.51 |
| Balance sheet | |||||
| Total assets | 74.56 | 59.77 | 2.72 | 6.17 | 7.53 |
| Net worth | 68.79 | 56.79 | 2.95 | 4.92 | 5.56 |
| Total debt | 4.73 | 2.76 | 1.61 | 1.37 | 1.74 |
| Cash & bank | 13.61 | 11.78 | 0.02 | 0.11 | 0.80 |
| Net working capital | 33.69 | 27.38 | (4.31) | 1.04 | 2.57 |
| Cash flow | |||||
| Cash from operations | 2.25 | 2.78 | (0.33) | 0.16 | 0.00 |
| Cash from investing | (8.63) | (11.30) | (0.71) | (0.30) | 0.00 |
| Cash from financing | 8.21 | 6.96 | 0.95 | (0.55) | 0.00 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 17.72 | 16.75 | 18.34 | 11.98 | 11.67 | 10.71 | 11.27 | 7.49 |
| Revenue growth (YoY) | +51.8% | +56.4% | +62.7% | +60.0% | +43.0% | -0.4% | - | - |
| Other income | 0.24 | 0.45 | 0.13 | 0.35 | 0.30 | 0.27 | 0.64 | 0.12 |
| EBITDA | 2.23 | 1.94 | 2.26 | 1.87 | 1.76 | 1.51 | 1.31 | 0.64 |
| EBITDA margin | +12.6% | +11.6% | +12.3% | +15.6% | +15.1% | +14.1% | +11.6% | +8.5% |
| Depreciation | 0.26 | 0.25 | 0.25 | 0.26 | 0.26 | 0.25 | 0.25 | 0.16 |
| Interest | 0.16 | 0.13 | 0.12 | 0.07 | 0.10 | 0.05 | 0.07 | 0.03 |
| Profit before tax | 2.05 | 2.01 | 2.02 | 1.89 | 1.70 | 1.48 | 1.63 | 0.57 |
| Tax | 0.50 | 0.49 | 0.52 | 0.47 | 0.42 | 0.37 | 0.39 | 0.14 |
| Net profit | 1.55 | 1.52 | 1.50 | 1.42 | 1.28 | 1.11 | 1.24 | 0.43 |
| EPS (₹) | 0.78 | 0.76 | 0.86 | 0.88 | 0.78 | 0.66 | 0.80 | 0.32 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 42.13 | 32.49 | 27.93 | 18.32 | 25.41 | 11.99 | 0.00 |
| Revenue growth | +29.7% | +16.3% | +52.5% | -27.9% | +111.9% | - | - |
| EBITDA | 3.37 | 1.71 | 1.62 | 0.96 | 1.32 | 0.52 | (0.17) |
| EBITDA margin | +8.0% | +5.3% | +5.8% | +5.2% | +5.2% | +4.3% | - |
| Profit before tax | 4.72 | 2.32 | 0.99 | 1.02 | 0.95 | 0.83 | 0.13 |
| Net profit | 3.59 | 1.31 | 0.76 | 0.74 | 0.72 | 0.61 | 0.13 |
| Net profit margin | +8.5% | +4.0% | +2.7% | +4.0% | +2.8% | +5.1% | - |
| EPS (₹) | 2.50 | 1.26 | 0.58 | 0.92 | 0.85 | 1.61 | 0.33 |
| Balance sheet | |||||||
| Total assets | 69.17 | 58.18 | 50.68 | 29.48 | 33.26 | 14.35 | 5.74 |
| Net worth | 67.51 | 56.42 | 50.68 | 29.43 | 28.63 | 12.53 | 5.48 |
| Total debt | 1.67 | 1.75 | 0.00 | 0.05 | 4.63 | 1.83 | 0.26 |
| Cash & bank | 13.55 | 11.51 | 13.35 | 0.61 | 0.22 | 4.07 | 0.02 |
| Net working capital | 25.59 | 27.05 | 29.43 | 8.15 | 11.01 | 8.44 | 2.14 |
| Cash flow | |||||||
| Cash from operations | 6.92 | 2.05 | (7.08) | 4.22 | (7.73) | (0.83) | 0.77 |
| Cash from investing | (11.21) | (9.85) | (0.55) | 0.87 | 0.59 | (2.94) | (0.65) |
| Cash from financing | 6.33 | 5.97 | 20.36 | (4.70) | 3.28 | 7.81 | (0.13) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.66 | 14.18 | 15.90 | 9.57 | 9.20 | 7.45 | 7.09 | 6.91 |
| Revenue growth (YoY) | +59.4% | +90.3% | +124.3% | +38.5% | +18.9% | -30.7% | - | - |
| Other income | 0.48 | 0.68 | 0.45 | 0.56 | 0.56 | 0.55 | 0.87 | 0.10 |
| Total expenses | 13.49 | 13.27 | 14.68 | 8.70 | 8.48 | 6.93 | 6.58 | 6.46 |
| EBITDA | 1.17 | 0.91 | 1.22 | 0.87 | 0.72 | 0.52 | 0.51 | 0.45 |
| EBITDA margin | +8.0% | +6.4% | +7.7% | +9.1% | +7.8% | +7.0% | +7.2% | +6.5% |
| Depreciation | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 |
| Interest | 0.07 | 0.04 | 0.04 | 0.04 | 0.07 | 0.02 | 0.04 | 0.02 |
| Profit before tax | 1.43 | 1.40 | 1.48 | 1.24 | 1.06 | 0.90 | 1.19 | 0.38 |
| Tax | 0.32 | 0.34 | 0.37 | 0.29 | 0.25 | 0.22 | 0.30 | 0.10 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 17.72 | 16.75 | 18.34 | 11.98 | 11.67 | 10.71 | 11.27 | 7.49 |
| Revenue growth (YoY) | +51.8% | +56.4% | +62.7% | +60.0% | +43.0% | -0.4% | - | - |
| Other income | 0.24 | 0.45 | 0.13 | 0.35 | 0.30 | 0.27 | 0.64 | 0.12 |
| EBITDA | 2.23 | 1.94 | 2.26 | 1.87 | 1.76 | 1.51 | 1.31 | 0.64 |
| EBITDA margin | +12.6% | +11.6% | +12.3% | +15.6% | +15.1% | +14.1% | +11.6% | +8.5% |
| Depreciation | 0.26 | 0.25 | 0.25 | 0.26 | 0.26 | 0.25 | 0.25 | 0.16 |
| Interest | 0.16 | 0.13 | 0.12 | 0.07 | 0.10 | 0.05 | 0.07 | 0.03 |
| Profit before tax | 2.05 | 2.01 | 2.02 | 1.89 | 1.70 | 1.48 | 1.63 | 0.57 |
| Tax | 0.50 | 0.49 | 0.52 | 0.47 | 0.42 | 0.37 | 0.39 | 0.14 |
| Net profit | 1.55 | 1.52 | 1.50 | 1.42 | 1.28 | 1.11 | 1.24 | 0.43 |
| EPS (₹) | 0.78 | 0.76 | 0.86 | 0.88 | 0.78 | 0.66 | 0.80 | 0.32 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Revenue | 52.57 | 37.66 | 10.40 | 4.27 | 2.36 |
| Revenue growth | +39.6% | - | +143.6% | +80.9% | - |
| Other income | 1.16 | 1.20 | 0.01 | 0.04 | 0.04 |
| Total expenses | 45.25 | 34.90 | 14.90 | 4.95 | 1.99 |
| Employee cost | 0.48 | 0.29 | 2.58 | 0.78 | 0.18 |
| EBITDA | 7.32 | 2.76 | (4.50) | (0.68) | 0.37 |
| EBITDA margin | +13.9% | +7.3% | -43.3% | -15.9% | +15.7% |
| Depreciation | 1.02 | 0.74 | 0.19 | 0.17 | 0.08 |
| Interest | 0.36 | 0.17 | 0.24 | 0.19 | 0.09 |
| Profit before tax | 7.10 | 3.05 | (4.92) | (1.00) | 0.24 |
| Tax | 1.79 | 0.75 | (1.32) | (0.21) | 0.05 |
| Net profit | 5.31 | 1.86 | (1.89) | (0.45) | 0.19 |
| Net profit margin | +10.1% | +4.9% | -18.2% | -10.5% | +8.1% |
| EPS (₹) | 3.71 | 1.68 | (4.99) | 0.00 | 0.51 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Equity & liabilities | |||||
| Share capital | 14.35 | 13.76 | 3.82 | 3.82 | 3.82 |
| Reserves & surplus | 50.38 | 43.03 | (0.87) | 1.10 | 1.74 |
| Shareholders' funds (net worth) | 68.79 | 56.79 | 2.95 | 4.92 | 5.56 |
| Minority interest | 1.05 | 0.22 | (1.83) | (0.12) | 0.22 |
| Secured loans | 4.73 | 2.76 | 1.61 | 1.37 | 1.74 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 4.73 | 2.76 | 1.61 | 1.37 | 1.74 |
| Total liabilities | 74.56 | 59.77 | 2.72 | 6.17 | 7.53 |
| Assets | |||||
| Gross block | 25.95 | 25.95 | 1.75 | 1.71 | 2.27 |
| Net block | 22.10 | 23.11 | 1.75 | 1.71 | 1.69 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 15.29 | 7.15 | 0.10 | 1.72 | 3.17 |
| Inventories | 3.97 | 5.77 | 3.21 | 2.31 | 3.10 |
| Sundry debtors | 20.22 | 10.79 | 1.18 | 0.86 | 1.46 |
| Cash & bank balances | 13.61 | 11.78 | 0.02 | 0.11 | 0.80 |
| Loans & advances | 9.60 | 4.54 | 0.62 | 0.89 | 0.61 |
| Total current assets | 47.40 | 32.88 | 5.03 | 4.17 | 5.97 |
| Total current liabilities | 13.71 | 5.50 | 9.34 | 3.13 | 3.40 |
| Net working capital | 33.69 | 27.38 | (4.31) | 1.04 | 2.57 |
| Total assets | 74.56 | 59.77 | 2.72 | 6.17 | 7.53 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Opening cash | 11.78 | 13.35 | 0.11 | 0.80 | 0.00 |
| Net cash from operating activities | 2.25 | 2.78 | (0.33) | 0.16 | 0.00 |
| Net cash from investing activities | (8.63) | (11.30) | (0.71) | (0.30) | 0.00 |
| Net cash from financing activities | 8.21 | 6.96 | 0.95 | (0.55) | 0.00 |
| Net change in cash | 1.83 | (1.57) | (0.09) | (0.69) | 0.00 |
| Closing cash | 13.61 | 11.78 | 0.02 | 0.11 | 0.80 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Growth | |||||
| Sales growth | +39.6% | - | +143.6% | +80.9% | - |
| EBITDA growth | +165.2% | - | -561.8% | -283.8% | - |
| PBT growth | +132.8% | +9998.0% | -392.0% | - | +9997.0% |
| Net income growth | +185.5% | - | -320.0% | -336.8% | - |
| Revenue CAGR (3Y) | +130.9% | +151.8% | - | - | - |
| EBITDA CAGR (3Y) | - | +95.4% | - | - | - |
| Profitability & leverage | |||||
| Net income margin | +10.1% | +6.1% | -34.6% | -18.5% | +8.1% |
| Return on capital employed | +11.2% | +4.8% | 0.0% | 0.0% | +4.7% |
| Return on net worth | +8.5% | +3.3% | 0.0% | 0.0% | +3.6% |
| Debt / equity | 0.06 | 0.05 | 0.38 | 0.30 | 0.31 |
| Long-term debt / equity | 0.04 | 0.04 | 0.26 | 0.09 | 0.09 |
| Interest cover | 5.71 | 8.42 | -5.12 | -22.35 | 31.03 |
| Efficiency & per share | |||||
| Fixed asset turnover | 2.03 | 1.45 | 6.01 | 2.15 | 1.04 |
| Inventory turnover | 10.79 | 6.53 | 3.77 | 1.58 | 0.76 |
| Debtors turnover | 3.39 | 3.49 | 10.20 | 3.68 | 1.62 |
| EPS (₹) | 3.71 | 1.68 | (4.99) | 0.00 | 0.51 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 45.12 | 41.26 | 7.71 | 12.89 | 14.56 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.66 | 14.18 | 15.90 | 9.57 | 9.20 | 7.45 | 7.09 | 6.91 |
| Revenue growth (YoY) | +59.4% | +90.3% | +124.3% | +38.5% | +18.9% | -30.7% | - | - |
| Other income | 0.48 | 0.68 | 0.45 | 0.56 | 0.56 | 0.55 | 0.87 | 0.10 |
| Total expenses | 13.49 | 13.27 | 14.68 | 8.70 | 8.48 | 6.93 | 6.58 | 6.46 |
| EBITDA | 1.17 | 0.91 | 1.22 | 0.87 | 0.72 | 0.52 | 0.51 | 0.45 |
| EBITDA margin | +8.0% | +6.4% | +7.7% | +9.1% | +7.8% | +7.0% | +7.2% | +6.5% |
| Depreciation | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 |
| Interest | 0.07 | 0.04 | 0.04 | 0.04 | 0.07 | 0.02 | 0.04 | 0.02 |
| Profit before tax | 1.43 | 1.40 | 1.48 | 1.24 | 1.06 | 0.90 | 1.19 | 0.38 |
| Tax | 0.32 | 0.34 | 0.37 | 0.29 | 0.25 | 0.22 | 0.30 | 0.10 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 42.13 | 32.49 | 27.93 | 18.32 | 25.41 | 11.99 | 0.00 |
| Revenue growth | +29.7% | +16.3% | +52.5% | -27.9% | +111.9% | - | - |
| Other income | 2.13 | 1.37 | 0.18 | 0.85 | 0.67 | 0.46 | 0.43 |
| Total expenses | 38.76 | 30.78 | 26.31 | 17.36 | 24.09 | 11.47 | 0.17 |
| Employee cost | 0.23 | 0.22 | 0.16 | 0.23 | 0.23 | 0.12 | 0.07 |
| EBITDA | 3.37 | 1.71 | 1.62 | 0.96 | 1.32 | 0.52 | (0.17) |
| EBITDA margin | +8.0% | +5.3% | +5.8% | +5.2% | +5.2% | +4.3% | - |
| Depreciation | 0.59 | 0.63 | 0.66 | 0.63 | 0.56 | 0.06 | 0.06 |
| Interest | 0.19 | 0.13 | 0.15 | 0.16 | 0.48 | 0.09 | 0.07 |
| Profit before tax | 4.72 | 2.32 | 0.99 | 1.02 | 0.95 | 0.83 | 0.13 |
| Tax | 1.13 | 0.57 | 0.23 | 0.26 | 0.23 | 0.22 | 0.00 |
| Net profit | 3.59 | 1.31 | 0.76 | 0.74 | 0.72 | 0.61 | 0.13 |
| Net profit margin | +8.5% | +4.0% | +2.7% | +4.0% | +2.8% | +5.1% | - |
| EPS (₹) | 2.50 | 1.26 | 0.58 | 0.92 | 0.85 | 1.61 | 0.33 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 14.35 | 13.76 | 12.87 | 8.32 | 8.32 | 3.82 | 3.82 |
| Reserves & surplus | 49.10 | 42.66 | 37.81 | 21.11 | 20.31 | 2.37 | 1.66 |
| Shareholders' funds (net worth) | 67.51 | 56.42 | 50.68 | 29.43 | 28.63 | 12.53 | 5.48 |
| Secured loans | 1.67 | 1.75 | 0.00 | 0.05 | 3.08 | 0.20 | 0.26 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 1.55 | 1.63 | 0.00 |
| Total debt | 1.67 | 1.75 | 0.00 | 0.05 | 4.63 | 1.83 | 0.26 |
| Total liabilities | 69.17 | 58.18 | 50.68 | 29.48 | 33.26 | 14.35 | 5.74 |
| Assets | |||||||
| Gross block | 16.99 | 16.99 | 15.69 | 15.34 | 15.12 | 0.52 | 0.52 |
| Net block | 13.67 | 14.26 | 13.56 | 13.88 | 14.29 | 0.25 | 0.31 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 15.15 | 7.07 | 4.02 | 0.05 | 0.20 | 0.22 | 0.50 |
| Inventories | 3.97 | 4.02 | 3.39 | 0.91 | 5.46 | 0.06 | 0.00 |
| Sundry debtors | 18.89 | 10.14 | 13.13 | 7.11 | 4.56 | 3.41 | 0.00 |
| Cash & bank balances | 13.55 | 11.51 | 13.35 | 0.61 | 0.22 | 4.07 | 0.02 |
| Loans & advances | 2.04 | 2.90 | 1.06 | 0.67 | 2.20 | 3.16 | 2.14 |
| Total current assets | 38.45 | 28.57 | 30.93 | 9.30 | 12.44 | 10.70 | 2.16 |
| Total current liabilities | 12.86 | 1.52 | 1.50 | 1.15 | 1.43 | 2.26 | 0.02 |
| Net working capital | 25.59 | 27.05 | 29.43 | 8.15 | 11.01 | 8.44 | 2.14 |
| Total assets | 69.17 | 58.18 | 50.68 | 29.48 | 33.26 | 14.35 | 5.74 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 11.51 | 13.35 | 0.61 | 0.22 | 4.07 | 0.02 | 0.03 |
| Net cash from operating activities | 6.92 | 2.05 | (7.08) | 4.22 | (7.73) | (0.83) | 0.77 |
| Net cash from investing activities | (11.21) | (9.85) | (0.55) | 0.87 | 0.59 | (2.94) | (0.65) |
| Net cash from financing activities | 6.33 | 5.97 | 20.36 | (4.70) | 3.28 | 7.81 | (0.13) |
| Net change in cash | 2.04 | (1.83) | 12.73 | 0.40 | (3.85) | 4.05 | (0.01) |
| Closing cash | 13.55 | 11.51 | 13.35 | 0.61 | 0.22 | 4.07 | 0.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +29.7% | +16.3% | +52.5% | -27.9% | +111.9% | - | - |
| EBITDA growth | +97.1% | +5.6% | +68.8% | -27.3% | +153.9% | +405.9% | - |
| PBT growth | +103.5% | +134.3% | -2.9% | +7.4% | +14.5% | +538.5% | +18.2% |
| Net income growth | +174.1% | +72.4% | +2.7% | +2.8% | +18.0% | +369.2% | - |
| Revenue CAGR (3Y) | +32.0% | +8.5% | +32.6% | - | +302.4% | +186.5% | -100.0% |
| EBITDA CAGR (3Y) | +52.0% | +9.0% | +46.1% | - | +87.6% | +16.4% | - |
| Profitability & leverage | |||||||
| Net income margin | +8.5% | +5.4% | +2.7% | +4.2% | +2.8% | +5.1% | - |
| Return on capital employed | +7.7% | +3.8% | +2.8% | +3.8% | +6.0% | +9.2% | +3.5% |
| Return on net worth | +5.8% | +2.4% | +1.9% | +2.7% | +3.5% | +6.8% | +2.4% |
| Debt / equity | 0.03 | 0.02 | 0.00 | 0.08 | 0.16 | 0.12 | 0.05 |
| Long-term debt / equity | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.04 |
| Interest cover | 6.83 | 12.04 | 15.63 | 48.48 | 63.16 | 19.57 | -30.43 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.48 | 1.99 | 1.80 | 1.20 | 3.25 | 23.06 | 0.00 |
| Inventory turnover | 10.55 | 8.77 | 12.99 | 5.75 | 9.21 | 399.67 | 0.00 |
| Debtors turnover | 2.90 | 2.79 | 2.76 | 3.14 | 6.38 | 7.03 | 0.00 |
| EPS (₹) | 2.50 | 1.26 | 0.58 | 0.92 | 0.85 | 1.61 | 0.33 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 44.22 | 41.00 | 39.37 | 35.38 | 34.43 | 16.19 | 14.35 |
To see the full year-wise statements and ratios of Eiko Lifesciences Limited, buy the company report.
Board of directors and KMP of Eiko Lifesciences Limited
Eiko Lifesciences Limited currently reports 8 directors and 1 key managerial person. 21 former directors have served the organization.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Bhavesh Dhirajlal Tanna | Director | 26 Aug 2013 | 13 Years 2 Months | Current |
| Jaid Ismail Kojar Also directs: Eiko Scientific Solutions LLP, Techvertica Technologies Private Limited, Reflux Pharmaceuticals Private Limited and 1 more | Cfo | 09 Feb 2022 | 4 Years 9 Months | Current |
| Umesh Ravindranath More | Whole-Time Director | 12 Nov 2020 | 6 Years 0 Months | Current |
| Kajal Dhanpatraj Kothari Also directs: Fresh Box Media Private Limited | Director | 09 Sep 2020 | 6 Years 2 Months | Current |
| Laxmikant Ramprasad Kabra Also directs: Dhanraj Highrise LLP, Laxmikant Kabra & Co LLP, Eiko Scientific Solutions LLP and 1 more | Director | 26 Aug 2013 | 13 Years 2 Months | Current |
| Sumukh Prabhakar Vartak Also directs: Uv Wellness Private Limited | Whole-Time Director | 29 Jul 2025 | 1 Years 3 Months | Current |
Peer comparison
Eiko Lifesciences Limited is compared with the 7 companies closest to it by revenue in the Chemicals industry (API Manufacturers, Lifesciences, Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Eiko Lifesciences Limitedthis company | ₹52.57 Cr (FY 2026) | ₹5.31 Cr | 10.1% | 39.6% | Thane, Maharashtra, India | |
| Allegro Speciality Chemicals Private Limited | ₹38.95 Cr (FY 2025) | -21.0% | Hyderabad, Telangana, India | |||
| Blue Star Extrusion Private Limited | ₹38.76 Cr (FY 2025) | 83.0% | Sangli, Maharashtra, India | |||
| Nebula Healthcare Limited | ₹38.59 Cr (FY 2025) | 4.0% | Ahmedabad, Gujarat, India | |||
| Almon Healthcare Private Limited | ₹38.26 Cr (FY 2025) | 58.0% | Ahmedabad, Gujarat, India | |||
| Vadivarhe Speciality Chemicals Limited | ₹38.17 Cr (FY 2025) | -6.0% | Igatpuri, Maharashtra, India | |||
| Leomine Organics Private Limited | ₹38.15 Cr (FY 2025) | 82.0% | Mumbai, Maharashtra, India | |||
| Resipol Adhesives Private Limited | ₹38.08 Cr (FY 2025) | -64.0% | Kadi, Gujarat, India |
To see the full peer comparison of Eiko Lifesciences Limited, buy the company report.
Auditor
Eiko Lifesciences Limited is audited by Thanawala & Company for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Thanawala & Company | FY 2023 | 110948W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 39.90%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 60.10%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 39.90% | 39.90% | 37.20% | 37.20% |
| Public | 60.10% | 60.10% | 62.80% | 62.80% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 30 Sep 2025 | 101172739 | Bank of India | ₹10 Cr | Open | |
| 30 Nov 2024 | 101031353 | Others | ₹1 Cr | Satisfied | |
| 13 May 2021 | 100452692 | Others | ₹7 Cr | Satisfied |
To see the full charge records of Eiko Lifesciences Limited, buy the company report.
Total charge records: 3 View all charges
Deals & funding
Eiko Lifesciences Limited has 48 deals on record (47 market trades, 1 funding round), with disclosed funding of ₹24.95 Cr; the latest was in June 2025.
Deals on record (5 of 48)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2025 | Market trade | ₹70.8 Lakh | Buyer: an individual Seller: 2B Black Bio LLP |
| Feb 2025 | Market trade | ₹37 Lakh | Buyer: an individual Seller: 2B Black Bio LLP |
| Apr 2024 | Market trade | ₹1.06 Cr | Buyer: V Square Pharmachem Private Limited Seller: an individual |
| Mar 2024 | Market trade | ₹99.5 Lakh | Buyer: V Square Pharmachem Private Limited Seller: an individual |
| Aug 2023 | Market trade | ₹26.1 Lakh | Seller: Dhwaja Shares & Securities Private Limited |
To see the full deal history of Eiko Lifesciences Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Eiko Lifesciences Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
Eiko Lifesciences Limited has 1 MSME Form 1 return on record for the period ending Mar 2021, listing 6 overdue payments to 2 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (2 of 2)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Omkar Speciality Chemicals Limited | |||
| Delicare Lifesciences Private Limited |
To see the full MSME payment records of Eiko Lifesciences Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Eiko Lifesciences has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACN0917C1ZZ | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Eiko Lifesciences Limited, buy the company report.
Recent activity
Eiko Lifesciences Limited has 28 board changes on record since 2011: 9 appointments and 19 cessations. The latest: Suraj Mahadev Gaikwad was appointed as Additional Director on 24 Aug 2026.
25 earlier events are in the company report.
News
Frequently asked questions
Eiko Lifesciences is an active public limited company based in Thane, Maharashtra, India. The company works in specialty chemicals, within the chemicals and materials industry. It was incorporated on 07 January 1977 (49+ years old) and is registered under CIN L65993MH1977PLC258134. Listed on BSE: 540204.
Eiko Lifesciences reported revenue of ₹52.57 Cr for FY 2025-26 (up 39.6% YoY) based on consolidated financials.
Eiko Lifesciences has 9 current directors and KMP:
- Umesh Ravindranath More - Whole-Time Director
- Sumukh Prabhakar Vartak - Whole-Time Director
- Bhavesh Dhirajlal Tanna - Director
- Kajal Dhanpatraj Kothari - Director
- Laxmikant Ramprasad Kabra - Director
- Rajkumar Govindas Baheti - Director
- Hasti Arjav Doshi - Director
- Suraj Mahadev Gaikwad - Additional Director
- Jaid Ismail Kojar - Cfo
The latest financial statements of Eiko Lifesciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 05 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Eiko Lifesciences is 27AAACN0917C1ZZ, registered in Maharashtra.
The CIN (Corporate Identification Number) of Eiko Lifesciences is L65993MH1977PLC258134. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Eiko Lifesciences is a listed company as per MCA records. Its shares are listed on BSE (code: 540204).
Eiko Lifesciences was incorporated on 07 January 1977, making it 49+ years old. It is registered with the Registrar of Companies, Mumbai.
Eiko Lifesciences has 48 deals on record (47 market trades, 1 funding round), with disclosed funding of ₹24.95 Cr; the latest was in June 2025.
The peers of Eiko Lifesciences by revenue are Allegro Speciality Chemicals Private Limited, Blue Star Extrusion Private Limited, Nebula Healthcare Limited, Almon Healthcare Private Limited, Vadivarhe Speciality Chemicals Limited and 2 more, all in the Chemicals industry (API Manufacturers, Lifesciences, Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Suraj Mahadev Gaikwad was appointed as Additional Director on 24 Aug 2026. Sumukh Prabhakar Vartak was appointed as Whole-Time Director on 29 Jul 2025. Hasti Arjav Doshi was appointed as Director on 03 Sep 2024. Eiko Lifesciences has 28 board changes on record in total.
Yes, Eiko Lifesciences is registered as a small enterprise under Udyam registration (number: UDYAM-MH-33-0313779).

